SynCore Biotechnology   Report issue

For profit Phase 2 Phase 3
Founded: Yilan Taiwan (2008)

Organization Overview

First Clinical Trial
2011
NCT01159522
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

SynCore Biotechnology Co., Ltd.

Active Ingredients

Drugs in Phase 3 Trials (2)

gemcitabine (gemzar) (2 trials)

paclitaxel (taxol) (2 trials)

Drugs in Phase 2 Trials (1)

scb01a (4 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 3)

Breast Neoplasms (Phase 3)

Carcinoma, Squamous Cell (Phase 2)

Head and Neck Neoplasms (Phase 2)

Neoplasms (Phase 1)

Pancreatic Neoplasms (Phase 3)

Squamous Cell Carcinoma of Head and Neck (Phase 2)

Triple Negative Breast Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 6
  • # of Trial APIs: 3